Dermata Therapeutics- Warrants (13/08/2026) Total Liabilities

As of the most recent data (June 2026), DRMAW shows a total liabilities of $1.8M. That compares with $1M in the prior-year period — up 78.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRMAW's total liabilities is now $1.8M (was $1M) — a 78.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Dermata Therapeutics- Warrants (13/08/2026) is outperforming or lagging.

Tracking DRMAW's total liabilities over time shows whether Dermata Therapeutics- Warrants (13/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $1.8M That compares with $1M in the prior-year period — up 78.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Dermata Therapeutics- Warrants (13/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $1.8M) with ownership activity and broader fundamentals.

Dermata Therapeutics- Warrants (13/08/2026)'s total liabilities is $1.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.